The positive Phase 2 data from Oncolytics Biotech's BRACELET-1 trial indicates that the combination of paclitaxel plus pelareorep is more effective than paclitaxel monotherapy in treating metastatic breast cancer. This may lead to increased investor interest in the company and a potential short-term boost in its stock price, as it demonstrates the potential for future revenue growth and market share in the cancer treatment space.